articleThe LancetMay 1, 2020BRONZE OA

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

IFIvan Fan-Ngai HungKLKwok-Cheung LungEYEugene Yuk-Keung TsoRLRaymond LiuTWTom Wai‐Hin Chung

Queen Mary Hospital · University of Hong Kong · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,567
total citations
FWCI
37.84
Percentile
100%
References
37
Citations per year

Authors

44

Topics & keywords

Topics
Keywords
  • Medicine
  • Lopinavir
  • Ritonavir
  • Ribavirin
  • Internal medicine
  • Lopinavir/ritonavir
  • Clinical endpoint
  • Adverse effect
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding